ASCO GU 2024 Prostate Cancer

REVIEW UroToday

Viewing 1-20 of 95 articles

ASCO GU 2024: The NEPI Trial: A Randomized Phase I/II Study of Neoadjuvant Treatment with 177-Lutetium-PSMA-617 with or without Ipilimumab in Patients with Very High-Risk Prostate Cancer Who Are Candidates for Radical Prostatectomy

ASCO GU 2024: A Randomized, Non-Comparative, Phase II Multicenter Trial of Short-Term Darolutamide Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-Risk Prostate Cancer: DARIUS (AFU-GETUG P15)

ASCO GU 2024: Assessing the Clinical Utility of Rapid Post-Therapy Whole-Body Digital SPECT/CT in Evaluating Early Treatment Response of 177Lu-PSMA-617 Treatment

ASCO GU 2024: Association Between SPECT/CT Total Tumor Volume and New Lesions in Early Cycles of 177Lu-PSMA-617 and PFS and OS in Men with mCRPC

ASCO GU 2024: Association Between PET-Based TheraP Eligibility and 177Lu-PSMA-617 Outcomes in VISION-Eligible Patients with mCRPC

ASCO GU 2024: Implementation Outcomes of a Multidisciplinary Approach for Lu177-PSMA-617 Therapy

ASCO GU 2024: Baseline Characteristics of Patients with PSMA-PET–positive and –Negative Disease with High-Risk of BCR After RP in the Ongoing Phase 3 PRIMORDIUM Study

ASCO GU 2024: Evaluating Clinical Outcomes with Systemic Therapy Given After Progression on PSMA Radioligand Therapy in Patients with mCRPC

ASCO GU 2024: Setting the Stage: Biochemical Recurrence After Local Treatment for Prostate Cancer

ASCO GU 2024: Low and High Volume Disease in mHSPC, from CHAARTED to PSMA-PET: An International Multicenter Retrospective Study

ASCO GU 2024: Patient Reported Outcomes Among Patients with mCRPC by HRR Mutations Gene Clusters: Findings from the Phase 3 TALAPRO-2 Study Cohort 2

ASCO GU 2024: Patient Outcomes After Therapy with 177Lu-PSMA-617 for mCRPC: A Tertiary Center Experience

ASCO GU 2024: Patient-Reported Outcomes in Patients with BRCA1/2-Altered mCRPC Receiving Niraparib with Abiraterone Acetate and Prednisone: Results from MAGNITUDE Study

ASCO GU 2024: Patient-Reported Outcomes with Talazoparib + Enzalutamide vs. Placebo + Enzalutamide in Men with mCRPC: Subgroup Analysis of Patients with Novel Hormonal Therapy Pretreatment in the TALAPRO-2 Study

ASCO GU 2024: Prognostic Value of AI–Driven Tumor Estimation of PSMA PET Total Tumor Burden in Newly Diagnosed High-Volume mHSPC

ASCO GU 2024: Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in mCRPC

ASCO GU 2024: OASIS: Survival Outcomes of Apalutamide as a Starting Treatment - Impact in Real-World Patients with mCSPC

ASCO GU 2024: ProstACT GLOBAL: A Phase 3 Study of Best Standard of Care with and without 177Lu-DOTA-rosopatamab (TLX591) for Patients with PSMA Expressing mCRPC Progressing Despite Prior Treatment with a Novel Androgen Axis Drug

ASCO GU 2024: Real-world Comparison of PSA Response in Patients with mCSPC Treated with Apalutamide or Enzalutamide

ASCO GU 2024: 3TMPO: Prognostic Value of FDG, PSMA, and DOTATATE Uptake on PET Imaging in mCRPC

1
2
3
4
5